Chief Executive Officer and founder, Mai-Britt Zocca, Ph.D.
Experienced biotech executive (15+y) having worked in a number of start-ups with significant insight into translational and clinical immune oncology.
Chief Scientific Officer and founder, Professor Mads Hald Andersen
Professor and Director of CCIT (Center for Cancer Immune Therapy at Herlev University Hospital. Mads Hald Andersen has received several honors for his scientific work and is the author of more than 130 papers. MHA has founded and co-founded several spin out companies with a successful sale of Survac in 2006.
Chief Medical Officer, Eva Ehrnrooth, M.D., Ph.D.
Board-certified oncologist who most recently served as executive director, the global clinical programme team leader at Boehringer Ingelheim. She held clinical development positions of increasing responsibility at Boehringer Ingelheim between 2010 and 2017. Previously Dr. Ehrnrooth was a medical director at Genmab and has been working as oncologist in the Department of Oncology at National Danish Hospital.
Chief Financial Officer, Mikkel Dybkjaer, Ms.Econ.
+20 years of financial and strategic experience from pharma/biotech companies (e.g. Lundbeck and Genmab) and management consultancy companies (e.g. Accenture). Involved in multiple high value licensing deals/company acquisitions.
VP, Translational Research, Ayako Wakatsuki Pedersen, PhD
Experienced cancer immunologist (15+ years) with preclinical development of immunotherapeutic drugs in biotechs (8+ years).